Switch theme
Sign up to access all valuation multiples
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
2003
312
LTM Revenue $97.9M
LTM EBITDA -$9.9M
$122M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MDxHealth has a last 12-month revenue (LTM) of $97.9M and a last 12-month EBITDA of -$9.9M.
In the most recent fiscal year, MDxHealth achieved revenue of $90.0M and an EBITDA of -$22.0M.
MDxHealth expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MDxHealth valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $97.9M | XXX | $90.0M | XXX | XXX | XXX |
| Gross Profit | $60.9M | XXX | $55.1M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | -$9.9M | XXX | -$22.0M | XXX | XXX | XXX |
| EBITDA Margin | -10% | XXX | -24% | XXX | XXX | XXX |
| EBIT | -$18.6M | XXX | -$24.0M | XXX | XXX | XXX |
| EBIT Margin | -19% | XXX | -27% | XXX | XXX | XXX |
| Net Profit | -$32.0M | XXX | -$38.1M | XXX | XXX | XXX |
| Net Margin | -33% | XXX | -42% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $4.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MDxHealth's stock price is $2.
MDxHealth has current market cap of $104M, and EV of $122M.
See MDxHealth trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $122M | $104M | XXX | XXX | XXX | XXX | $-0.88 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MDxHealth has market cap of $104M and EV of $122M.
MDxHealth's trades at 1.4x EV/Revenue multiple, and -5.6x EV/EBITDA.
Equity research analysts estimate MDxHealth's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MDxHealth has a P/E ratio of -3.3x.
See valuation multiples for MDxHealth and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $104M | XXX | $104M | XXX | XXX | XXX |
| EV (current) | $122M | XXX | $122M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | -12.4x | XXX | -5.6x | XXX | XXX | XXX |
| EV/EBIT | -6.6x | XXX | -5.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.3x | XXX | -2.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMDxHealth's last 12 month revenue growth is 19%
MDxHealth's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
MDxHealth's rule of 40 is -24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MDxHealth's rule of X is 39% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MDxHealth and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | -10% | XXX | -24% | XXX | XXX | XXX |
| EBITDA Growth | -158% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -24% | XXX | -5% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 88% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MDxHealth acquired XXX companies to date.
Last acquisition by MDxHealth was XXXXXXXX, XXXXX XXXXX XXXXXX . MDxHealth acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MDxHealth founded? | MDxHealth was founded in 2003. |
| Where is MDxHealth headquartered? | MDxHealth is headquartered in United States of America. |
| How many employees does MDxHealth have? | As of today, MDxHealth has 312 employees. |
| Who is the CEO of MDxHealth? | MDxHealth's CEO is Mr. Michael K. McGarrity. |
| Is MDxHealth publicy listed? | Yes, MDxHealth is a public company listed on NAS. |
| What is the stock symbol of MDxHealth? | MDxHealth trades under MDXH ticker. |
| When did MDxHealth go public? | MDxHealth went public in 2008. |
| Who are competitors of MDxHealth? | Similar companies to MDxHealth include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of MDxHealth? | MDxHealth's current market cap is $104M |
| What is the current revenue of MDxHealth? | MDxHealth's last 12 months revenue is $97.9M. |
| What is the current revenue growth of MDxHealth? | MDxHealth revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of MDxHealth? | Current revenue multiple of MDxHealth is 1.3x. |
| Is MDxHealth profitable? | Yes, MDxHealth is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MDxHealth? | MDxHealth's last 12 months EBITDA is -$9.9M. |
| What is MDxHealth's EBITDA margin? | MDxHealth's last 12 months EBITDA margin is -10%. |
| What is the current EV/EBITDA multiple of MDxHealth? | Current EBITDA multiple of MDxHealth is -12.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
